“ATR-258, a synthetic small molecule, has favourable pharmacokinetics and in Phase 1 clinical trials has been administered just once a day as a capsule, making it a straightforward, patient-friendly ...

Crime bosses called her 'Barbie' - Magdalena Sadlo, 30, was sentenced to 14 years in prison after using her management skills ...

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendric cell neoplasm ...

ProteinQure’s lead candidate, PQ203, is a first-in-class peptide-drug conjugate designed to target the sortilin receptor, which is overexpressed in many solid tumors, including TNBC.